Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 4, 2010, Pages 503-510

  Li, Yu Hong ^a   Luo, Hui Yan ^a   Wang, Feng Hua ^a   Wang, Zhi Qiang ^a   Qiu, Miao Zhen ^a   Shi, Yan Xia ^a   Xiang, Xiao Juan ^a   Chen, Xiao Qing ^a   He, You Jian ^a   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Capecitabine; Maintenance therapy; Metastatic colorectal cancer; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG; XELOX;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CHINESE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOXICITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; KIDNEY FAILURE; LARYNX SPASM; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN ALLERGY; STOMACH PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 77949261564     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0682-5     Document Type: Article

References (26)

1. CP Belani J Barstis MC Perry, et al. 2003 Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation J Clin Oncol 21 15 2933 2939 10.1200/JCO.2003.02.563 1:CAS:528:DC%2BD2cXpsVKjt7g%3D 12885812 (Pubitemid 46621844)
2. JL Blum SE Jones AU Buzdar, et al. 1999 Multicenter phase II study of capecitabine in paclitaxel refractory metastatic breast cancer J Clin Oncol 17 2 485 493 1:CAS:528:DyaK1MXht1Wmurw%3D 10080589
3. T Brodowicz M Krzakowski M Zwitter, et al. 2006 Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial Lung Cancer 52 2 155 163 10.1016/j.lungcan.2006.01.006 10.1016/j.lungcan.2006.01.006 16569462
4. J Cassidy C Twelves E Van Cutsem, et al. 2002 First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin Ann Oncol 13 4 566 575 10.1093/annonc/mdf089 1:STN:280:DC%2BD38zhsVyntg%3D%3D 12056707 (Pubitemid 34461140)
5. J Cassidy J Tabernero C Twelves, et al. 2004 XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer J Clin Oncol 22 11 2084 2091 10.1200/JCO.2004.11.069 10.1200/JCO.2004.11. 069 1:CAS:528:DC%2BD2cXpsVWlsL8%3D 15169795 (Pubitemid 41095141)
6. J Cassidy S Clarke E Díaz-Rubio, et al. 2008 Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 12 2006 2012 10.1200/JCO.2007.14.9898 10.1200/JCO.2007.14.9898 1:CAS:528:DC%2BD1cXlvFaqs7s%3D 18421053
7. JP Caussanel F Lévi S Brienza, et al. 1990 Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate J Natl Cancer Inst 82 12 1046 1050 10.1093/jnci/82.12.1046 1:STN:280:DyaK3c3ntFalsg%3D%3D 2348469
8. K Chen MJ Jing QT Jiang, et al. 2006 The molecular epidemiology study of environment exposure and metabolic enzyme gene polymorphism in colorectal cancer Chin J Epidemiol 27 10 905 908
9. P Comella R Casaretti C Sandomenico, et al. 2008 Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence Drugs 68 7 949 961 10.2165/00003495-200868070-00005 1:CAS:528:DC%2BD1cXnvVSisb8%3D 18457461 (Pubitemid 351652923)
10. A de Gramont A Figer M Seymour, et al. 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 16 2938 2947 10944126
11. Díaz-Rubio E, Tabernero J, Gómez-España A et al (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25(27):4224-4230. doi: 10.1200/JCO.2006.09.8467 (Pubitemid 47548562)
12. Goebel FM, Lledo G, Chibaudel B et al (2007) Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol 25(18): abstract 4013
13. Goh BC, Soo RA, Lim SW et al (2008) Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping. J Clin Oncol 26(15S):abstract 2507
14. RM Goldberg DJ Sargent RF Morton, et al. 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 1 23 30 10.1200/JCO.2004.09.046 10.1200/JCO.2004.09.046 1:CAS:528: DC%2BD2cXpsVKitbY%3D 14665611 (Pubitemid 41095110)
15. A Jemal T Murray E Ward, et al. 2005 Cancer statistics, 2005 CA Cancer J Clin 55 1 10 30 10.3322/canjclin.55.1.10 10.3322/canjclin.55.1.10 15661684
16. K Jordan O Kellner T Kegel, et al. 2004 Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers Clin Colorectal Cancer 4 1 46 50 10.3816/CCC.2004.n.009 10.3816/CCC.2004.n.009 1:CAS:528:DC%2BD2cXlsFCiuro%3D 15207020
17. M Mackean A Planting C Twelves, et al. 1998 Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer J Clin Oncol 16 9 2977 2985 1:CAS:528:DyaK1cXmtFSls7k%3D 9738566
18. T Makatsoris HP Kalofonos G Aravantinos, et al. 2005 A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer Int J Gastrointest Cancer 35 2 103 109 10.1385/IJGC:35:2:103 1:CAS:528:DC%2BD2MXltVKrtL8%3D 15879624
19. M Miwa M Ura M Nishida, et al. 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 8 1274 1281 10.1016/S0959-8049(98)00058-6 1:CAS:528: DyaK1cXltlCgsrk%3D 9849491 (Pubitemid 28342121)
20. M Nakajima T Fukami H Yamanaka, et al. 2006 Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations Clin Pharmacol Ther 80 3 282 297 10.1016/j.clpt.2006.05.012 10.1016/j.clpt.2006.05.012 1:CAS:528:DC%2BD28XptFCnsr4%3D 16952495 (Pubitemid 44313906)
21. S Novello P Bruzzi C Barone, et al. 2007 Phase III study in stage IV non-small cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone Ann Oncol 18 5 903 908 10.1093/annonc/mdm061 10.1093/annonc/mdm061 1:STN:280:DC%2BD2s3ns1yhtQ%3D%3D 17351253 (Pubitemid 47054089)
22. R Scalamogna S Brugnatelli C Tinelli, et al. 2007 UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen Oncology 72 5-6 267 273 10.1159/000113037 10.1159/000113037 1:CAS:528:DC%2BD1cXhs1yisrs%3D 18187947 (Pubitemid 351238136)
23. W Scheithauer GV Kornek M Raderer, et al. 2003 Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 21 7 1307 1312 10.1200/JCO.2003.09.016 1:CAS:528:DC%2BD2cXpsVWqsLk%3D 12663719 (Pubitemid 46606408)
24. W Scheithauer J McKendrick S Begbie, et al. 2003 Oral capecitabine as an alternative to i.v. 5-fluorouracilbased adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Ann Oncol 14 12 1735 1743 10.1093/annonc/mdg500 1:STN:280:DC%2BD3srltVWgtg%3D%3D 14630678 (Pubitemid 38029045)
25. C Twelves A Wong MP Nowacki, et al. 2005 Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 26 2696 2704 10.1056/NEJMoa043116 1:CAS:528:DC%2BD2MXls1SktL0%3D 15987918 (Pubitemid 41007824)
26. E Van Cutsem PM Hoff P Harper, et al. 2004 Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials Br J Cancer 90 6 1190 1197 10.1038/sj.bjc.6601676 10.1038/sj.bjc.6601676 15026800 (Pubitemid 38496812)